Pandemic COVID-19, an update of current status and new therapeutic strategies
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00210-022-02265-9.pdf
Reference48 articles.
1. Ader F, Bouscambert-Duchamp M, Hites M et al (2021) Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. https://doi.org/10.1016/S1473-3099(21)00485-0
2. Agostini ML, Pruijssers AJ, Chappell JD et al (2019) Small-molecule antiviral β-d-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J Virol 93(24):301348–301419. https://doi.org/10.1128/JVI.01348-19
3. Callaway E (2021) Heavily mutated Omicron variant puts scientists on alert. Nature News. https://www.nature.com/articles/d41586-021-03552-w. Accessed 16 Dec 2021
4. Callaway E, Ledford H (2021) How bad is Omicron? What Scientists Know so Far. Nature 600(7888):197–199. https://doi.org/10.1038/d41586-021-03614-z
5. CDC (2021) Science Brief: Omicron (B.1.1.529) Variant. CDC. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-omicron-variant.html. Accessed 16 Dec 2021
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. COVID-19 Pandemic: Therapeutic Strategies and Vaccines;International Journal of Molecular Sciences;2023-12-31
2. Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes;Frontiers in Cellular and Infection Microbiology;2023-10-19
3. Pairwise synthetic cytotoxicity between Paxlovid and 100 frequently prescribed FDA-approved small molecule drugs on liver cells;Toxicology and Applied Pharmacology;2023-10
4. Antibiotic Consumption in Primary Care in Costa Rica and Italy: A Retrospective Cross-Country Analysis;Cureus;2023-07-05
5. Association between microbiota and immune response to Sars-CoV-2 infection;Infectious Diseases Now;2023-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3